Close

Ocugen (OCGN) Enters Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in US, Europe and Japan

Go back to Ocugen (OCGN) Enters Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in US, Europe and Japan

Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan

September 28, 2022 6:30 AM EDT

Ocugens intranasal candidate is one of the worlds most advanced intranasal COVID-19 vaccinesIntranasal vaccine is designed to curb virus transmission and confer protective immunity

MALVERN, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the company has entered into an exclusive license agreement with Washington University in St. Louis, MO... More